UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

Annals of oncology, 2016-10, Vol.27 (10), p.1953-1958

2016

Volltextzugriff (PDF)

Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer

Thrombosis research, 2017-06, Vol.154, p.28-34

2017

Volltextzugriff (PDF)

115 Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S41-S41

2016

Volltextzugriff (PDF)

Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis

Thrombosis research, 2015-12, Vol.136 (6), p.1120-1125

2015

Volltextzugriff (PDF)

70 Heterogeneity of programmed death-ligand 1 expression in multifocal lung cancer

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S25-S26

2016

Volltextzugriff (PDF)

Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S67-S68

2014

Volltextzugriff (PDF)

Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials

Thrombosis research, 2015-12, Vol.136 (6), p.1169-1173

2015

Volltextzugriff (PDF)

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Annals of oncology, 2022-05, Vol.33 (5), p.488-499

2022

Volltextzugriff (PDF)

EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S414

2022

Volltextzugriff (PDF)

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Annals of oncology, 2020-02, Vol.31 (2), p.310-317

2020

Volltextzugriff (PDF)

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer

Journal of thrombosis and haemostasis, 2016-09, Vol.14 (9), p.1773-1778

2016

Volltextzugriff (PDF)

84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups

Annals of oncology, 2020-09, Vol.31, p.S274-S275

2020

Volltextzugriff (PDF)

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of oncology, 2022-11, Vol.33 (11), p.1168-1178

2022

Volltextzugriff (PDF)

Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas

International journal of radiation oncology, biology, physics, 2019-05, Vol.104 (1), p.237-238

2019

Volltextzugriff (PDF)

17P Effects of tumour mutation burden on the antigen presentation pathway

Annals of oncology, 2020-12, Vol.31, p.S1422-S1423

2020

Volltextzugriff (PDF)

P3.12C.01 BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S341-S341

2024

Volltextzugriff (PDF)

1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours

Annals of oncology, 2020-09, Vol.31, p.S708-S708

2020

Volltextzugriff (PDF)

1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study

Annals of oncology, 2024-09, Vol.35, p.S789-S790

2024

Volltextzugriff (PDF)

MA17.10 miRNA Signatures In Mesothelioma and their Associations with Outcomes with Immune Checkpoint Inhibitors

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S165

2023

Volltextzugriff (PDF)

EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S631

2023

Volltextzugriff (PDF)

EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S726-S727

2023

Volltextzugriff (PDF)

Pulmonary sarcomatoid carcinoma—a new hope

Annals of oncology, 2017-07, Vol.28 (7), p.1417-1418

2017

Volltextzugriff (PDF)

P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S278-S279

2024

Volltextzugriff (PDF)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib

Annals of oncology, 2016-11, Vol.27 (11), p.2111-2117

2016

Volltextzugriff (PDF)

LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Annals of oncology, 2021-09, Vol.32, p.S1341-S1342

2021

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(68)
Buchkapitel
(4)

Sprache

Englisch
(71)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Humans
(16)
Male
(9)
Middle Aged
(9)
Cardiovascular System & Cardiology
(8)
Hematology
(8)
Peripheral Vascular Disease
(8)
Hematology, Oncology And Palliative Medicine
(7)
Oncology
(7)
Adult
(6)
Aged
(6)
Female
(6)
Biological And Medical Sciences
(4)
Lung Cancer
(4)
Medical Sciences
(4)
Cardiology. Vascular System
(3)
Hplc
(3)
Litter Chemistry
(3)
Litter Quality
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer

115 Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer

Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis

70 Heterogeneity of programmed death-ligand 1 expression in multifocal lung cancer

Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer

Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer

84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas

17P Effects of tumour mutation burden on the antigen presentation pathway

P3.12C.01 BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer

1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours

1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study

MA17.10 miRNA Signatures In Mesothelioma and their Associations with Outcomes with Immune Checkpoint Inhibitors

EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression

EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

Pulmonary sarcomatoid carcinoma—a new hope

P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib

LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Suchergebnisse filtern